Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M. & Fitzmaurice, C. World burden of urologic cancers, 1990–2013. Eur. Urol. 71(3), 437–446 (2017).
Siegel, R. L., Miller, Okay. D., Wagle, N. S. & Jemal, A. Most cancers statistics, 2023. CA Most cancers J. Clin. 73(1), 17–48 (2023).
Grunwald, V. et al. An interdisciplinary consensus on the administration of bone metastases from renal cell carcinoma. Nat. Rev. Urol. 15(8), 511–521 (2018).
Bianchi, M. et al. Distribution of metastatic websites in renal cell carcinoma: A population-based evaluation. Ann. Oncol. 23(4), 973–980 (2012).
Santoni, M. et al. Bone metastases in sufferers with metastatic renal cell carcinoma: Are they all the time related to poor prognosis?. J. Exp. Clin. Most cancers Res. 34, 10 (2015).
Woodward, E. et al. Skeletal problems and survival in renal most cancers sufferers with bone metastases. Bone 48(1), 160–166 (2011).
Smith, M. R. Zoledronic acid to stop skeletal problems in most cancers: Corroborating the proof. Most cancers Deal with. Rev. 31(Suppl 3), 19–25 (2005).
Hua, Okay.-C. & Hu, Y.-C. Institution of predictive mannequin for sufferers with kidney most cancers bone metastasis: A research based mostly on SEER database. Transl. Androl. Urol. 9(2), 523–543 (2020).
Nakatani, Okay., Nakamoto, Y., Saga, T., Higashi, T. & Togashi, Okay. The potential medical worth of FDG-PET for recurrent renal cell carcinoma. Eur. J. Radiol. 79(1), 29–35 (2011).
Szendroi, A. et al. Prognostic elements and survival of renal clear cell carcinoma sufferers with bone metastases. Pathol. Oncol. Res. 16(1), 29–38 (2010).
Zhou, X. et al. Synergies of antiangiogenic remedy and immune checkpoint blockade in renal cell carcinoma: From theoretical background to medical actuality. Entrance. Oncol. 10, 1321 (2020).
Liu, R. et al. Value-effectiveness evaluation of nivolumab plus cabozantinib versus sunitinib as first-line remedy in superior renal cell carcinoma. Immunotherapy 14(11), 859–869 (2022).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for superior renal-cell carcinoma. N. Engl. J. Med. 380(12), 1116–1127 (2019).
Beckendorf, V. et al. Requirements, choices, and suggestions for radiotherapy of kidney most cancers. Most cancers Radiother. 4(3), 223–233 (2000).
Arcangeli, G. et al. The responsiveness of bone metastases to radiotherapy: The impact of web site, histology and radiation dose on ache aid. Radiother. Oncol. 14(2), 95–101 (1989).
Zhou, Y. et al. Prognostic nomograms and Aggtrmmns scoring system for predicting general survival and cancer-specific survival of sufferers with kidney most cancers. Most cancers Med. 9(8), 2710–2722 (2020).
Hou, G. et al. Building and validation of a novel prognostic nomogram for sufferers with sarcomatoid renal cell carcinoma: A SEER-based research. Int. J. Clin. Oncol. 25(7), 1356–1363 (2020).
Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P. & Fleischmann, J. Cytoreductive surgical procedure for stage IV renal cell carcinoma. J. Urol. 154(1), 32–34 (1995).
Jackson, B. L., Fowler, S., Williams, S. T., British Affiliation of Urological Surgeons. Perioperative outcomes of cytoreductive nephrectomy within the UK in 2012. BJU Int. 116(6), 905–910 (2015).
Umbreit, E. C., McIntosh, A. G., Suk-Ouichai, C., Karam, J. A. & Wooden, C. G. The present function of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J. Urol. 37(1), 13–16 (2021).
Silberstein, J. L. et al. Systematic classification and prediction of problems after nephrectomy in sufferers with metastatic renal cell carcinoma (RCC). BJU Int. 110(9), 1276–1282 (2012).
Mejean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379(5), 417–427 (2018).
Zekri, J., Ahmed, N., Coleman, R. E. & Hancock, B. W. The skeletal metastatic problems of renal cell carcinoma. Int. J. Oncol. 19(2), 379–382 (2001).
Wang, Okay. et al. Survival nomogram for sufferers with bone metastatic renal cell carcinoma: A population-based research. Int. Braz. J. Urol. 47(2), 333–349 (2021).
Jung, S. T., Ghert, M. A., Harrelson, J. M. & Scully, S. P. Therapy of osseous metastases in sufferers with renal cell carcinoma. Clin. Orthop. Relat. Res. 409, 223–231 (2003).
Siva, S. et al. Consensus assertion from the Worldwide Radiosurgery Oncology Consortium for Kidney for major renal cell carcinoma. Future Oncol. 12(5), 637–645 (2016).
Siva, S. et al. Pooled evaluation of stereotactic ablative radiotherapy for major renal cell carcinoma: A report from the Worldwide Radiosurgery Oncology Consortium for Kidney (IROCK). Most cancers 124(5), 934–942 (2018).
Duggan, M. A., Anderson, W. F., Altekruse, S., Penberthy, L. & Sherman, M. E. The surveillance, epidemiology, and finish outcomes (SEER) program and pathology towards strengthening the vital relationship. Am. J. Surg. Pathol. 40(12), E94–E102 (2016).
Jiang, L., Wang, C., Tong, Y., Jiang, J. & Zhao, D. Net-based nomogram and danger stratification system constructed for predicting the general survival of older adults with major kidney most cancers after surgical resection. J. Most cancers Res. Clin. Oncol. 149(13), 11873–11889 (2023).
Mathew, G., Agha, R., SSTROCSS Group. Strengthening the reporting of cohort, cross-sectional and case-control research in surgical procedure. Int. J. Surg. 2021, 96 (2021).
Nahm, F. S. Receiver working attribute curve: Overview and sensible use for clinicians. Korean J. Anesthesiol. 75(1), 25–36 (2022).
Vickers, A. J. & Holland, F. Choice curve evaluation to judge the medical advantage of prediction fashions. Backbone J. 21(10), 1643–1648 (2021).
Van Calster, B. et al. Reporting and deciphering resolution curve evaluation: A information for investigators. Eur. Urol. 74(6), 796–804 (2018).
Nakagawa, S. & Cuthill, I. C. Impact dimension, confidence interval and statistical significance: A sensible information for biologists. Biol. Rev. 82(4), 591–605 (2007).
Johnson, D. E., Kaesler, Okay. E. & Samuels, M. L. Is nephrectomy justified in sufferers with metastatic renal carcinoma?. J. Urol. 114(1), 27–29 (1975).
Montie, J. E. et al. The function of adjunctive nephrectomy in sufferers with metastatic renal cell carcinoma. J. Urol. 117(3), 272–275 (1977).
Austin, P. C., Jembere, N. & Chiu, M. Propensity rating matching and sophisticated surveys. Stat. Strategies Med. Res. 27(4), 1240–1257 (2018).
Fuchs, B., Trousdale, R. T. & Rock, M. G. Solitary bony metastasis from renal cell carcinoma—Significance of surgical therapy. Clin. Orthop. Relat. Res. 431, 187–192 (2005).
Ruatta, F. et al. Prognosis of renal cell carcinoma with bone metastases: Expertise from a big most cancers centre. Eur. J. Most cancers 107, 79–85 (2019).
Zheng, W. et al. Growth and validation of a nomogram to foretell general survival for sufferers with metastatic renal cell carcinoma. BMC Most cancers 20(1), 1066 (2020).
Huang, G. et al. Growth and validation of a prognostic nomogram for predicting cancer-specific survival in sufferers with metastatic clear cell renal carcinoma: A research based mostly on SEER database. Entrance. Oncol. 12, 949058 (2022).
Lu, Z., He, W., Zhou, J., Yang, C. & Xiang, R. Building and validation of a novel prognostic nomogram for sufferers with metastatic renal cell carcinoma: A SEER-based research. J. Int. Med. Res. 50(6), 3000605221105367 (2022).
Brookman-Could, S. et al. Options related to recurrence past 5 years after nephrectomy and nephron-sparing surgical procedure for renal cell carcinoma: Growth and inner validation of a danger mannequin (PRELANE rating) to foretell late recurrence based mostly on a big multicenter database (CORONA/SATURN Undertaking). Eur. Urol. 64(3), 472–477 (2013).
Fottner, A. et al. Bone metastases from renal cell carcinoma: Affected person survival after surgical therapy. BMC Musculoskelet. Disord. 11, 145 (2010).
McNichols, D. W., Segura, J. W. & DeWeerd, J. H. Renal cell carcinoma: Lengthy-term survival and late recurrence. J. Urol. 126(1), 17–23 (1981).
Shiono, S. et al. Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy. Jpn. J. Clin. Oncol. 34(1), 46–49 (2004).
Assouad, J. et al. Methods and outcomes in pulmonary and extrapulmonary metastases from renal cell most cancers. Eur. J. Cardio-Thorac. Surg. 33(5), 794–798 (2008).
Chen, F. et al. Pulmonary resection for metastasis from renal cell carcinoma. Work together. Cardiovasc. Thorac. Surg. 7(5), 825–828 (2008).
Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335(12), 865–875 (1996).
Jiang, L., Tong, Y., Jiang, J. & Zhao, D. Individualized evaluation predictive fashions for danger and general survival in aged sufferers of major kidney most cancers with bone metastases: A big population-based research. Entrance. Med. 10, 1127625 (2023).
Paner, G. P. et al. Updates within the eighth version of the tumor-node-metastasis staging classification for urologic cancers. Eur. Urol. 73(4), 560–569 (2018).
Zhou, H. et al. Threat elements, prognostic elements, and nomograms for bone metastasis in sufferers with newly identified clear cell renal cell carcinoma: A big population-based research. Entrance. Surg. 9, 877653 (2022).
Wang, Okay., Li, Y., Wang, D. & Zhou, Z. Net-based dynamic nomograms for predicting general survival and cancer-specific survival in breast most cancers sufferers with lung metastases. J. Pers. Med. 13(1), 43 (2023).
